A clinical trial to study effectiveness and safety of Acrivastine capsules in comparison with Chlorpheniramine maleate tablets in patients suffering from allergic rhinitis
Phase 3
Completed
- Conditions
- Health Condition 1: null- Allergic rhinitisHealth Condition 2: J309- Allergic rhinitis, unspecified
- Registration Number
- CTRI/2010/091/001368
- Lead Sponsor
- Cadila Healthcare Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
1.Patients of either sex of 18 to 65 years of age
2.Established diagnosis of allergic rhinitis
3.Informed consent
Exclusion Criteria
1.Pregnancy & Lactation.
2.Significant renal impairment.
3.Narrow-angle glaucoma, GI or GUT obstruction.
4.Patients with acute attack of bronchial asthma or those on corticosteroids.
5.Nasal structural abnormalities
6.Upper respiratory tract infection
7.Hypersensitivity to study medications
8.Patients with any other serious concurrent illness or malignancy
9.Continuing history of alcohol and / or drug abuse
10.Recent participation in another clinical trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in the total symptom scoreTimepoint: 0,1,2 weeks
- Secondary Outcome Measures
Name Time Method The change in the total and individual nasal and ocular symptom scoresTimepoint: 0,1,2 weeks